NCT04437836View on ClinicalTrials.gov

Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2023

Conditions
Clinical Trial
Interventions
DRUG

Evaluation of high dose rifampicin in children

Evaluation of severity of adverse event from grade 1 to 5

Trial Locations (4)

+255

Kilimanjaro Clinical Research Institute, Moshi

Unknown

Hydom Hospital, Babati

Mt. Meru Hospital, Arusha

Huruma Hospital, Moshi

Sponsors
All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Kilimanjaro Clinical Research Institute

OTHER

NCT04437836 - Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic | Biotech Hunter | Biotech Hunter